Top News from IASLC 18th World Conference on Lung Cancer

Takeda Presents Updated Results from Pivotal Phase 2 ALTA Trial of ALUNBRIGTM (brigatinib) in ALK-Positive Non-Small Cell Lung Cancer 

October 16, 2017

Takeda Pharmaceutical Company Limited has announced that data from the pivotal Phase 2 ALTA (ALK in Lung Cancer Trial of AP26113) clinical trial evaluating ALUNBRIGTM (brigatinib) in patients with locally advanced or metastatic anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who have progressed on Crizotinib were presented in an oral session at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC). The presentation shared updated safety and efficacy data from the trial as of February 21, 2017. Updated Results Continue to Support the Efficacy and Safety Findings for ALUNBRIG with the 180 mg Dosing Regimen in Patients with Advanced ALK+ NSCLC Who Have Progressed on Crizotinib.

Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational Alk-Inhibitor Lorlatinib In Alk-Positive and Ros1-Positive Advanced Non-Small Cell Lung Cancer

October 16, 2017

Pfizer Inc. has announced full results from the Phase 2 clinical trial of the investigational, next-generation tyrosine kinase inhibitor lorlatinib that exhibited clinically meaningful activity against lung tumors and brain metastases in a range of patients with ALK-positive and ROS1-positive advanced non-small cell lung cancer (NSCLC), including those who were heavily pretreated. Further, side effects were generally manageable and primarily mild to moderate in severity.

Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA® (ramucirumab) Phase 3 Subgroup Analysis

October 16, 2017

New subgroup analysis from Eli Lilly and Company’s Phase 3 REVEL trial of CYRAMZA® (ramucirumab) in advanced non-small cell lung cancer (NSCLC) was presented at the 18th WCLC in Yokohama, Japan. Specifically, these new data are an exploratory, post-hoc analysis focused on patients whose cancer rapidly progressed on first-line therapy. This new subgroup analysis focused on outcomes from patients according to their (time to progression) TTP on first-line treatment. Of the 1,253 patients enrolled in REVEL, on first-line therapy, 11 percent (n=133) had TTP ?9 weeks, 17 percent (n=209) had TTP ?12 weeks, and 28 percent (n=354) had TTP ?18 weeks.

Merck’s KEYTRUDA® (pembrolizumab) More Than Doubled Median Overall Survival Compared to Chemotherapy After Two Years of Follow Up in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with High Levels of PD-L1

October 18, 2017

Merck has announced the presentation of updated overall survival (OS) findings, a secondary endpoint, from the phase 3 KEYNOTE-024 trial evaluating KEYTRUDA® . (pembrolizumab), the company’s anti-PD-1 therapy, as a first-line monotherapy in patients with non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 (tumor proportion score [TPS] of 50 percent or more). The study included patients with squamous and nonsquamous NSCLC with no EGFR or ALK genomic tumor aberrations. With an additional six months of available data, results continue to show a reduction in the risk of death by 37 percent for KEYTRUDA compared to chemotherapy based on more than two years of median follow-up (HR, 0.63 [95% CI, 0.47–0.86]; nominal p=0.002).

AstraZeneca and Chi-Med’s savolitinib shows encouraging clinical activity in 2nd-line EGFR mutation-positive lung cancer with MET-amplification

17 October 2017

AstraZeneca and its partner Chi-Med have presented preliminary safety and clinical activity of savolitinib when given in combination with either Tagrisso (osimertinib) or Iressa (gefitinib) in two Phase Ib trials conducted in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) with MET-amplification who had progressed following 1st-line treatment with an EGFR inhibitor. In both trials, the addition of savolitinib (600mg, once daily), an investigational selective inhibitor of c-MET (mesenchymal epithelial transition factor) receptor tyrosine kinase, to osimertinib (80mg, once daily) or gefitinib (250mg, once daily) demonstrated preliminary anti-tumour activity.

Top News from IASLC 18th World Conference on Lung Cancer last edit: 2017-10-22T16:52:05+00:00 da Luca

Leave a Reply

*The views and opinions expressed on IgeaHub belong to the authors only. They do not represent the views or opinions of any company or organization.

Follow Us

Join us

All rights reserved. Terms of use and Privacy Policy

Design by PT Webmaster

%d bloggers like this:
Skip to toolbar